You are here: Industry Insights > cancer

News List

Imfinzi Approved in US for Less-Frequent, Fixed-Dose Use americanpharmaceuticalreview
December 08, 2020
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy ..
Merck KGaA signs deal with Artios Pharma for cancer drugs research expresspharma
December 07, 2020
Artios will receive $30 million in up-front and near-term payments, plus double-digit option fees and up $860 million total milestones per target.
China's Taiwan, China-based Enterprises of AP Biosciences and LuminX Novel Cancer Treatments prnasia
December 01, 2020
In recent years, an increasing number of drugs have been granted breakthrough therapy designation in the United States, encouraging more companies to propose novel cancer treatment solutions.
Researchers warn pandemic could delay cancer advances ‘by almost a year’ pharmatimes
December 01, 2020
A new survey has detailed cancer researchers’ concerns that advances for patients could be delayed by nearly 18 months due to the impact of the COVID-19 pandemic.
New potential breast cancer drugs identified expresspharma
November 27, 2020
The potential drug offers hope for patients whose breast cancer has become resistant to traditional therapies.
Pierre Fabre Initiates Trial for Monoclonal Antibody Targeting VISTA Checkpoint in Solid Tumors americanpharmaceuticalreview
November 18, 2020
Pierre Fabre announced the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, a monoclonal antibody targeting VISTA, developed by ...
RedHill Receives Patent Allowance Covering Opaganib, RHB-107 Combination americanpharmaceuticalreview
November 13, 2020
RedHill Biopharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application related to the use of two of RedHill’s proprietary investigational compounds, opaganib (Yeliva®, ABC294640) and ..
Using Th17 cells researchers make adoptive T-cell transfer therapy viable europeanpharmaceuticalreview
November 12, 2020
Adoptive T-cell transfer therapy has had limited use due to the time involved in CD8+ T cell expansion, using a different type of T cell researchers were able to shorten this timeline, making the therapy more accessible.
First patient dosed in COVID-19 trial with allogeneic cell therapy europeanpharmaceuticalreview
November 10, 2020
The first patient with COVID-19 has been administered agenT-797, an allogeneic cell therapy made by Agenus Inc.
EC approves AstraZeneca and Merck’s Lynparza for two cancer types pharmaceutical-technology
November 06, 2020
AstraZeneca and Merck’s (MSD) Lynparza (olaparib) has secured approval from the European Commission for prostate cancer and ovarian cancer treatments in the European Union (EU).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page